Theravance Biopharma Presents Positive Results From a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor

DUBLIN, IRELAND--(Marketwired - Mar 18, 2016) - Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma" or the "Company") today announced that positive preclinical study results for TD-1473, a novel, potent, orally administered GI-targeted pan-Janus kinase (JAK) inhibitor, were presented today at the 11 th Congress of the European Crohn's and Colitis Organisation (ECCO) in Amsterdam. The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases, including ulcerative colitis. 

The study showed TD-1473 to be a potent and selective pan-JAK inhibitor capable of achieving high colonic drug levels without significant systemic exposure following oral dosing in a preclinical animal model. The study also demonstrated that TD-1473 was effective in reducing markers of colitis-related disease activity without suppressing systemic immune cells. In the same study, another JAK inhibitor (tofacitinib, currently in clinical development for moderate to severe ulcerative colitis) showed similar reductions in disease activity, but with higher concentrations of drug in the plasma than in the colon, and with evidence of systemic immune suppression.

"We view these results as strong foundational support from which to advance the TD-1473 program. The preclinical data suggest that systemic inhibition of JAK is not required to treat inflammation in the wall of the colon," said Brett Haumann, M.D., Chief Medical Officer at Theravance Biopharma. "Our research approach has been to develop targeted JAK inhibitors with anti-inflammatory activity that is limited specifically to the GI tract and reduces the risk of systemic side effects. Ulcerative colitis is a very debilitating disease affecting roughly 700,000 patients in the United States, and our vision is to develop a treatment option with a more favorable benefit/risk profile than current therapies. We look forward to further supplementing our scientific research of TD-1473 with the insights we gain from our ongoing Phase 1 clinical trial in healthy volunteers, which is expected to be completed during the first half of this year. Assuming a positive outcome from that trial, we then intend to initiate a Phase 1b study in the second half of the year."

Comparing Preclinical Properties of TD-1473 and Tofacitinib

In one study, the preclinical properties of TD-1473, an oral pan-JAK inhibitor with activity that is specifically targeted to the inflamed wall of the GI tract, were compared to that of tofacitinib, an oral pan-JAK inhibitor with broad systemic exposure and activity. Data showed that both compounds behaved as potent pan-JAK inhibitors and were effective in reducing disease activity, using a number of measures of colonic inflammation similar to those seen in patients with ulcerative colitis. However, at doses providing similar reductions in disease activity, the ratio of drug in the systemic circulation versus the colon was much lower for TD-1473 than that of tofacitinib, and in contrast to tofacitinib, TD-1473 had no effect on systemic immune cells, demonstrating the GI-targeted activity of TD-1473.

Therapeutic Potential of Targeted vs. Systemic JAK Inhibition in Colitis

A second study compared the therapeutic potential of colon-targeted JAK inhibition to systemic JAK inhibition in a preclinical colitis model. Researchers showed that administration of tofacitinib directly into the colon (1 mg/kg BID) achieved similar reductions in colitis-related disease activity as orally dosed tofacitinib (15 mg/kg BID). These two routes of administration achieved similar levels of colonic exposure of tofacitinib, but the oral dose resulted in significantly higher systemic exposure. These findings suggest that a GI-targeted JAK inhibitor may provide clinical efficacy in the treatment of colitis and other inflammatory intestinal diseases without the need for high systemic exposure and the attendant risk of systemically-mediated adverse effects.

About TD-1473

TD-1473 is an internally discovered JAK inhibitor that has demonstrated a high affinity for each of the JAK family of enzymes (JAK1, JAK2, JAK3 and TYK2). Through the inhibition of these enzymes, TD-1473 interferes with the JAK/STAT signaling pathway and, in turn, modulates the activity of a wide range of pro-inflammatory cytokines. Importantly, TD-1473 is a GI-targeted treatment specifically designed to distribute to the tissues of the GI tract and to minimize systemic exposure. 

The Company is currently conducting a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 study of TD-1473 in healthy subjects, which is expected to be completed during the first half of 2016. The primary objective of the study is the evaluation of the safety and tolerability of single ascending doses and multiple ascending doses of TD-1473 in healthy subjects. A key secondary objective of the trial will be the characterization of pharmacokinetics related to TD-1473, which will help determine the amount of TD-1473 that enters systemic circulation following oral administration. Assuming positive results from the ongoing study, the Company intends to initiate a Phase 1b trial of TD-1473 in the second half of 2016.

About Theravance Biopharma

Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that make a difference in the lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop GI-targeted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol).

For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's strategies, plans and objectives, the Company's regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the Company's product and product candidates and the Company's expectations for product candidates through development and commercialization. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates are unsafe or ineffective, the feasibility of undertaking future clinical trials for our product candidates based on FDA policies and feedback, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize product and product candidates and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate expertise and supporting infrastructure. Other risks affecting Theravance Biopharma are described under the heading "Risk Factors" contained in Theravance Biopharma's Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2016. In addition to the risks described above and in Theravance Biopharma's other filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

Contact Information: Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com Tim Brons Vida Strategic Partners (media) 646-319-8981 tbrons@vidasp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 61

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 146

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 18

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 246

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 196

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 9

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 35

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 34

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 116

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Abacus Global Management Inc. Stock

Updated Category News Views 231

Wolf Popper LLP Initiates Investigation for Investors In response to potential investor claims, Wolf Popper LLP has begun an investigation concerning the common stock of Abacus Global Management, Inc. (ABL). This action comes in light of significant recent developments that have raised concerns among shareholders. Background on Abacus Global Management Abacus Global...

Continue Reading
LM Funding America Inc. Reports Q3 2024 Results and Outlook

Updated Category News Views 115

Business Update and Financial Highlights LM Funding America, Inc. (NASDAQ: LMFA) has recently shared its financial results for the third quarter of 2024. This Tampa-based company focuses on cryptocurrency mining and technological finance solutions, showcasing significant strategic developments in its operations. Bitcoin Holdings and Revenue Performance As of September 30,...

Continue Reading
Siete Foods' Juntos Fund Celebrates 15 Latino-Owned Businesses

Updated Category News Views 239

Siete Foods launched its Juntos Fund back in 2024, dishing out a hefty $300,000 to uplift Latino small business owners. This initiative aimed at breaking down barriers for Latino entrepreneurs who often struggle to secure the financial backing they need. The winners? A mix of vibrant eateries and innovative food ventures that embody the rich essence of Latino culture...

Continue Reading
Discover the Fascinating Marilyn Monroe in New Documentary

Updated Category News Views 319

Big Screen Entertainment Group Unveils Marilyn Monroe Documentary Big Screen Entertainment Group (OTC: BSEG) has generated excitement with the release of its first trailer for an upcoming documentary focusing on the legendary actress Marilyn Monroe. This film, titled "Hollywood Legends: The Marilyn Monroe Story," promises to be a captivating tribute that delves into not...

Continue Reading
Transforming Dealerships: FrogData's New Marketing Solution

Updated Category News Views 120

FrogData Introduces FixedOps Velocity for Dealerships FrogData, a leader in advanced data analytics for the automotive industry, has recently launched a groundbreaking marketing solution called FixedOps Velocity. This innovative platform is aimed at helping dealership service departments enhance their marketing strategies significantly. The announcement comes just ahead...

Continue Reading